Guideline Knowledge Base
Search versions, compare publication history, and download source files from a single client-ready portal.
Available Guidelines
214 matches
-
Imported from European Medicines Agency (https://www.ema.europa.eu/en/human-regulatory-overview/research-development/compliance-research-development/good-manufacturing-practice/good-manufacturing-practice-gmp-good-distribution-practice-gdp-inspectors-working-group).
-
NL: Uitvoeringsverordening (EU) 2021/1280 van de Commissie van 2 augustus 2021 betreffende maatregelen inzake goede distributiepraktijken voor werkzame stoffen die als grondstof worden gebruikt in diergeneesmiddelen overeenkomstig Verordening (EU) 2019/6. CELEX 32021R1280 — PB L 279 van 3.8.2021, blz. 1. Van toepassing vanaf 28 januari 2022. Bron: https://eur-lex.europa.eu/legal-content/NL/TXT/PDF/?uri=CELEX:32021R1280
-
Guidelines on principles of Good Distribution Practice of active substances for medicinal products for human use (2015/C 95/01)
Published en nlNL: Richtsnoeren van 19 maart 2015 inzake de beginselen van goede distributiepraktijken voor werkzame stoffen voor geneesmiddelen voor menselijk gebruik. CELEX 52015XC0321(01) — PB C 95 van 21.3.2015, blz. 1. GDP voor API's. Bron: https://eur-lex.europa.eu/legal-content/NL/TXT/PDF/?uri=CELEX:52015XC0321(01)
-
Commission Implementing Regulation (EU) 2021/1248 — good distribution practice for veterinary medicinal products
Published en nlNL: Uitvoeringsverordening (EU) 2021/1248 van de Commissie van 29 juli 2021 betreffende maatregelen inzake goede distributiepraktijken voor diergeneesmiddelen overeenkomstig Verordening (EU) 2019/6. CELEX 32021R1248 — PB L 272 van 30.7.2021, blz. 46. Van toepassing vanaf 28 januari 2022. Bron: https://eur-lex.europa.eu/legal-content/NL/TXT/?uri=CELEX%3A32021R1248
-
Guidelines on Good Distribution Practice of medicinal products for human use (2013/C 343/01)
Published en nlNL: Richtsnoeren van 5 november 2013 inzake goede distributiepraktijken voor geneesmiddelen voor menselijk gebruik. CELEX 52013XC1123(01) — PB C 343 van 23.11.2013, blz. 1. Vervangt de versie van 7 maart 2013 (PB C 68/01). Kerndocument GDP humaan (QP/RP). Bron: https://eur-lex.europa.eu/legal-content/NL/TXT/PDF/?uri=CELEX:52013XC1123(01)
-
Sets the criteria under which the FDA considers electronic records, electronic signatures and handwritten signatures executed to electronic records to be trustworthy, reliable and equivalent to paper records. Covers controls for closed and open systems, signature manifestations and record linking, and electronic signature components, controls and identification codes.
-
The FDA's core CGMP regulation for finished pharmaceuticals, covering organisation and personnel, buildings and facilities, equipment, control of components, production and process controls, packaging and labelling, holding and distribution, laboratory controls, records and reports, and returned and salvaged drug products. Amended by 89 FR 51769 (18 June 2024, effective 18 December 2025) to exclude medical gases.
-
Establishes the status and applicability of the FDA's current good manufacturing practice regulations for drugs, and the definitions used throughout parts 211, 213, 225 and 226. Amended by 89 FR 51769 (18 June 2024, effective 18 December 2025) to add part 213 for medical gases.
-
Imported from European Medicines Agency (https://www.ema.europa.eu/en/scientific-guidelines.xml).
-
Imported from European Medicines Agency (https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/pre-authorisation-guidance).
Get Guideline Updates in Your Mailbox
Subscribe for major GMP/GDP guideline changes, new publications and timeline updates.